Crizotinib
c-Met and ALK inhibitor / A potent and selective inhibitor of c-MET and ALK, IC50s=8 and 20 nM respectively.1 Inhibition of cell proliferation was associated with G1-S phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells (IC50=30 nM) but not in ALK-negative lymphoma cells.1 Exhibits cytoreductive antitumor efficacy via antiproliferative and antiangiogenic mechanisms.2 Clinically useful anticancer agent.3
Biochemicals & reagents
877399-52-5
PF-02341066; PF-1066
1) Christensen et al. (2007), Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma; Mol. Cancer Ther., 6 3314 2) Zou et al. (2007), An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiprofilerative and antiangiogenic mechanisms; Cancer Res., 67 4408 3) Bang et al. (2010), Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC); J. Clin. Oncol., 28 3
-20°C
TARGET: Kinase -- PATHWAY: Cell cycle; Apoptosis inducer; Proliferation -- RESEARCH AREA: Angiogenesis; Cell death -- DISEASE AREA: Cancer